Larry Hayward

Multi-omic machine learning predictor of breast cancer therapy response

Stephen‐John Sammut, Mireia Crispin‐Ortuzar, Suet‐Feung Chin et al. · Nature · 2021 · 642 citations · Full text

Medicine, Cancer Biology, Oncology +17

Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression

Tom Latham, C. Logan Mackay, Duncan Sproul et al. · Nucleic Acids Research · 2012 · 331 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Stephen Johnston, Lucy Kilburn, David Dodwell et al. · The Lancet Oncology · 2013 · 275 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Helena Earl, Louise Hiller, Janet Dunn et al. · The Lancet Oncology · 2015 · 134 citations · Full text

Medicine, Oncology, Pharmacology +17